First Time Loading...

Venus Medtech Hangzhou Inc
HKEX:2500

Watchlist Manager
Venus Medtech Hangzhou Inc Logo
Venus Medtech Hangzhou Inc
HKEX:2500
Watchlist
Price: 5.62 HKD Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Venus Medtech Hangzhou Inc

Wall Street analysts forecast Venus Medtech Hangzhou Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Venus Medtech Hangzhou Inc is 9.43 HKD with a low forecast of 5.05 HKD and a high forecast of 15.75 HKD.

Lowest Forecast
Wall Street Target
5.05 HKD
10% Downside
Average Forecast
Wall Street Target
9.43 HKD
68% Upside
Highest Forecast
Wall Street Target
15.75 HKD
180% Upside
Lowest
Price Target
5.05 HKD
10% Downside
Average
Price Target
9.43 HKD
68% Upside
Highest
Price Target
15.75 HKD
180% Upside
Venus Medtech Hangzhou Inc Competitors:
Price Targets
H
688581
Hangzhou AGS MedTech Co Ltd
79% Upside
PRN
Profound Medical Corp
61% Upside
1302
LifeTech Scientific Corp
50% Upside
DXR
Daxor Corp
142% Upside
H
688581
Hangzhou AGS MedTech Co Ltd
79% Upside
PRN
Profound Medical Corp
61% Upside
1302
LifeTech Scientific Corp
50% Upside
DXR
Daxor Corp
142% Upside
AFX
Carl Zeiss Meditec AG
20% Upside
SWAV
Shockwave Medical Inc
2% Downside
GEHC
GE Healthcare Technologies Inc
25% Upside
STE
STERIS plc
20% Upside

Revenue
Forecast

Revenue Estimate
Venus Medtech Hangzhou Inc

For the last 4 years the compound annual growth rate for Venus Medtech Hangzhou Inc's revenue is 37%. The projected CAGR for the next 4 years is 53%.

37%
Past Growth
53%
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Venus Medtech Hangzhou Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Venus Medtech Hangzhou Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Venus Medtech Hangzhou Inc's stock price target?
Price Target
9.43 HKD

According to Wall Street analysts, the average 1-year price target for Venus Medtech Hangzhou Inc is 9.43 HKD with a low forecast of 5.05 HKD and a high forecast of 15.75 HKD.

What is Venus Medtech Hangzhou Inc's Revenue forecast?
Projected CAGR
53%

For the last 4 years the compound annual growth rate for Venus Medtech Hangzhou Inc's revenue is 37%. The projected CAGR for the next 4 years is 53%.

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.